Physician Peter Nørregaard Hansen Department of Neurology, Odense University Hospital
Projektet i tal
OPEN undersøgelse/kliniske data
Forventet # af deltagere
Inkluderet antal deltagere
Inkluderede deltagere med prøver
Variation I axonal nerve function and clinical neurological function in chronic inflammatory demyelinating polyneuropathy (CIDP)
Full title: Variation I axonal nerve function and clinical neurological function in chronic inflammatory demyelinating polyneuropathy (CIDP) in relation to treatment with immunoglobulin intravenously (IVIG) and subcutaneously (SCIG).
Chronic inflammatory demyelinating polyneuropathy CIDP is a autoimmune disease characterized by demyelination of peripheral nerves resulting in reduction of nerve conduction velocity and conduction block causing paresis and sensory dysfunction in the extremities.
Immunoglobulin infusion is considered as first line treatment. However, the mechanism responsible for the effect is not completely understood.
We intend to study the mechanisms of immunoglobulin in CIDP patient.
Background: Chronic inflammatory demyelinating polyneuropathy CIDP is characterized by paresis and sensory dysfunction in the extremities. The disease is caused by demyelination of peripheral nerves resulting in reduced nerve conduction velocity and conduction block, but dysfunction of the axonal membrane itself may also play a significant role. The mechanism responsible for the effect of the main current treatment, immunoglobulin infusion, is not completely understood and clinical observations suggest that it is not limited to modulation of the immune system, but may also involve direct changes of axonal membrane properties.
Aim: We intend to study the clinical and neurophysiological effects of intravenous and subcutaneous immunoglobulins in CIDP patients with a specific focus on axonal function.
Method: Nerve excitability studies will be used to study the axonal membrane properties during treatment. Data will be correlated to clinical testing during steady-state treatment and during discontinuation of treatment.
Perspectives: The results may provide new insights into the pathophysiological mechanisms for nerve dysfunction and the mechanism of action of immunoglobulins in CIDP.
Description of the cohort
Patients with CIDP and MGUS-associated polyneuropathy that are associated with the neuromuscular clinic at the department of neurology at University Hospital of Odense.
Patients diagnosed with CIDP or MGUS-associated polyneuropathy
Ongoing treatment with IVIG or SCIG
Age between 18 and 80 years.
Known or obvious vascular disease in lower extremities.
Clinically significant affection of medulla spinalis, spinal roots or spinal stenosis.
Significant systemic disease
Patients with other diseases causing affected with of gait.
Data and biological material
Nerve excitability studies using Threshold Tracking
Nerve conduction studies
Collaborating researchers and departments
Department of Neurology, Odense University Hospital